Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA 510(k) clearance for ADAC Laboratories:

This article was originally published in Clinica

Executive Summary

The FDA has given ADAC Laboratories 510(k) clearance to market molecular coincidence detection with attenuation correction (MCD/ACTM) for use with its gamma cameras. MCD/AC is a further development to ADAC's MCD system which corrects image distortions created by non-uniform attenuation of soft tissue in the human body. The technology allows the company's nuclear medicine imaging systems to perform both single photon emission computed tomography and coincidence imaging. Coincidence imaging was previously confined to being available on expensive, dedicated positron emission tomography systems only.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT086574

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel